191 related articles for article (PubMed ID: 15179189)
21. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines.
Klisovic DD; Katz SE; Effron D; Klisovic MI; Wickham J; Parthun MR; Guimond M; Marcucci G
Invest Ophthalmol Vis Sci; 2003 Jun; 44(6):2390-8. PubMed ID: 12766035
[TBL] [Abstract][Full Text] [Related]
22. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
[TBL] [Abstract][Full Text] [Related]
23. Absence of mutations of the BRAF gene and constitutive activation of extracellular-regulated kinase in malignant melanomas of the uvea.
Weber A; Hengge UR; Urbanik D; Markwart A; Mirmohammadsaegh A; Reichel MB; Wittekind C; Wiedemann P; Tannapfel A
Lab Invest; 2003 Dec; 83(12):1771-6. PubMed ID: 14691295
[TBL] [Abstract][Full Text] [Related]
24. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
[TBL] [Abstract][Full Text] [Related]
25. Patient-derived xenografts recapitulate molecular features of human uveal melanomas.
Laurent C; Gentien D; Piperno-Neumann S; Némati F; Nicolas A; Tesson B; Desjardins L; Mariani P; Rapinat A; Sastre-Garau X; Couturier J; Hupé P; de Koning L; Dubois T; Roman-Roman S; Stern MH; Barillot E; Harbour JW; Saule S; Decaudin D
Mol Oncol; 2013 Jun; 7(3):625-36. PubMed ID: 23478236
[TBL] [Abstract][Full Text] [Related]
26. [THE BRAF MUTATION AND THE POSSIBILITIES OF UVEAL MELANOMA METASTASING PROGNOSTIC MARKERS IDENTIFICATION].
Horkovičová K; Markus J; Krčová I; Babál P; Kobzová D; Smolková B
Cesk Slov Oftalmol; 2016; 72(4):149-156. PubMed ID: 27860480
[TBL] [Abstract][Full Text] [Related]
27. Lack of SF3B1 R625 mutations in cutaneous melanoma.
Schilling B; Bielefeld N; Sucker A; Hillen U; Zimmer L; Schadendorf D; Zeschnigk M; Griewank KG
Diagn Pathol; 2013 May; 8():87. PubMed ID: 23694694
[TBL] [Abstract][Full Text] [Related]
28. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
29. Mutation analysis of the PTEN gene in uveal melanoma cell lines.
Naus NC; Zuidervaart W; Rayman N; Slater R; van Drunen E; Ksander B; Luyten GP; Klein A
Int J Cancer; 2000 Jul; 87(1):151-3. PubMed ID: 10861467
[No Abstract] [Full Text] [Related]
30. Detection of BRAF gene mutation in primary choroidal melanoma tissue.
Malaponte G; Libra M; Gangemi P; Bevelacqua V; Mangano K; D'Amico F; Mazzarino MC; Stivala F; McCubrey JA; Travali S
Cancer Biol Ther; 2006 Feb; 5(2):225-7. PubMed ID: 16410717
[TBL] [Abstract][Full Text] [Related]
31. B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcome.
Deichmann M; Thome M; Benner A; Näher H
Oncology; 2004; 66(5):411-9. PubMed ID: 15331929
[TBL] [Abstract][Full Text] [Related]
32. Spliceosome Mutations in Uveal Melanoma.
Nguyen JQN; Drabarek W; Yavuzyigitoglu S; Medico Salsench E; Verdijk RM; Naus NC; de Klein A; Kiliç E; Brosens E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333932
[TBL] [Abstract][Full Text] [Related]
33. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
[TBL] [Abstract][Full Text] [Related]
34. The T1796A mutation of the BRAF gene is absent in Spitz nevi.
Palmedo G; Hantschke M; Rütten A; Mentzel T; Hügel H; Flaig MJ; Yazdi AS; Sander CA; Kutzner H
J Cutan Pathol; 2004 Mar; 31(3):266-70. PubMed ID: 14984580
[TBL] [Abstract][Full Text] [Related]
35. The T1799A BRAF mutation is present in iris melanoma.
Henriquez F; Janssen C; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
[TBL] [Abstract][Full Text] [Related]
36. Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.
Goel VK; Lazar AJ; Warneke CL; Redston MS; Haluska FG
J Invest Dermatol; 2006 Jan; 126(1):154-60. PubMed ID: 16417231
[TBL] [Abstract][Full Text] [Related]
37. Driver mutations in melanoma: lessons learned from bench-to-bedside studies.
Mehnert JM; Kluger HM
Curr Oncol Rep; 2012 Oct; 14(5):449-57. PubMed ID: 22723080
[TBL] [Abstract][Full Text] [Related]
38. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
39. High BRAF mutation frequency does not characterize all melanocytic tumor types.
Saldanha G; Purnell D; Fletcher A; Potter L; Gillies A; Pringle JH
Int J Cancer; 2004 Sep; 111(5):705-10. PubMed ID: 15252839
[TBL] [Abstract][Full Text] [Related]
40. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
